| Predicted Trait | |
| Reported Trait | Nicotine metabolite ratio |
| Mapped Trait(s) | nicotine metabolite ratio (EFO_0007794) |
| Score Construction | |
| PGS Name | EUR_wGRS7 |
| Development Method | |
| Name | Genome-wide significant SNPs, conditional analysis |
| Parameters | NR |
| Variants | |
| Original Genome Build | NR |
| Number of Variants | 8 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000641 |
| Citation (link to publication) | El-Boraie A et al. Addict Biol (2019) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 2,451 individuals (100%) |
| PGS Evaluation | |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
Europe PMC: 30815984 |
933 individuals | European | PNAT2 |
GWAS Catalog: GCST009922 Europe PMC: 26407342 |
1,518 individuals | European | FINRISK, FinnTwin12, FinnTwin16, YFS |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM021363 | PSS011703| European Ancestry| 196 individuals |
PGP000641 | El-Boraie A et al. Addict Biol (2019) |
Reported Trait: Nicotine metabolite ratio in treatment-seeking smokers | — | — | R²: 0.411 | Sex, age, body mass index | — |
| PPM021364 | PSS011703| European Ancestry| 196 individuals |
PGP000641 | El-Boraie A et al. Addict Biol (2019) |
Reported Trait: Nicotine metabolism (slow vs normal) in treatment seeking smokers | — | AUROC: 0.78 [0.71, 0.85] | — | — | Slow metabolisers with a nicotine metabolite ratio (NMR) <0.31 vs normal metabolisers with a NMR ≥0.31. |
| PPM021365 | PSS011703| European Ancestry| 196 individuals |
PGP000641 | El-Boraie A et al. Addict Biol (2019) |
Reported Trait: Nicotine metabolism (slow vs normal) in treatment seeking smokers | — | AUROC: 0.78 [0.71, 0.86] | — | — | Slow metabolisers with a nicotine metabolite ratio (NMR) <0.26 vs normal metabolisers with a NMR ≥0.26. |
| PPM021409 | PSS011733| Multi-ancestry (including European)| 1,187 individuals |
PGP000655 | El-Boraie A et al. Clin Pharmacol Ther (2021) |Ext. |
Reported Trait: Nicotine metabolite ratio | — | — | R²: 0.261 | — | Log transformed nicotine metabolite ratio, 49.4% overlap with score development and testing samples |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS011703 | Participants were treatment seeking smokers. Using a nicotine metabolite ratio (NMR) cut-point of 0.31, individuals with slow nicotine metabolism were defined as having a NMR <0.31 whilst individuals with normal rates of nicotine metabolism were defined as having a NMR ≥0.31. Using a nicotine metabolite ratio (NMR) cut-point of 0.26, individuals with slow nicotine metabolism were defined as having a NMR <0.26 whilst individuals with normal rates of nicotine metabolism were defined as having a NMR ≥0.26. | — | 196 individuals | — | European | — | Q2L | — |
| PSS011733 | Participants were smokers. | — | 1,187 individuals | — | African American or Afro-Caribbean, Sub-Saharan African, European | African American or Afro-Caribbean and Sub-Saharan African = 954, European = 933 | KIS3, PNAT2 | — |